1. Hirotsu N, Saisho Y, Hasegawa ST. Clinical and virologic effects of four neuraminidase inhibitors in influenza A virus-infected children (aged 4–12 years): an open-label, randomized study in Japan. Expert Rev Anti-Infect Ther. 2018;16:173–82. https://doi.org/10.1080/14787210.2018.1421945. Epub 2017.
2. Rapiacta® for intravenous drip infusion. Package insert 2019. The Pharmaceuticals and Medical Devices Agency(PMDA), Tokyo, Japan. https://www.info.pmda.go.jp/go/pack/6250405A1032_1_11/. (Updated Sep 2019. Accessed 6 Mar 2020).
3. Sakai T, Nishimura SI, Naito T, Saito M. Influenza A virus hemagglutinin and neuraminidase act as novel motile machinery. Sci Rep. 2017;7:45043. https://doi.org/10.1038/srep45043.
4. Saisho Y, Ishibashi T, Fukuyama H, Fukase H, Shimada J. Pharmacokinetics and safety of intravenous peramivir, neuraminidase inhibitor of influenza virus in healthy Japanese subjects. Antivir Ther. 2017;22:313–23.
5. Kohno S, Kida H, Mizuguchi M, Shimada J, S-021812 Clinical Study Group. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother. 2010;54:4568.